We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Xceleron and Servier Sign Agreement to Accelerate Drug Development
News

Xceleron and Servier Sign Agreement to Accelerate Drug Development

Xceleron and Servier Sign Agreement to Accelerate Drug Development
News

Xceleron and Servier Sign Agreement to Accelerate Drug Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Xceleron and Servier Sign Agreement to Accelerate Drug Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Xceleron and Servier have announced that they have signed a twelve-month rolling Collaborative Agreement. 

The Agreement covers the provision by Xceleron of accelerator mass spectrometry (AMS) services to assist Servier in taking candidate drugs into humans much earlier than conventional Phase 1 studies.

This Agreement is the first of its kind whereby a pharma company is altering its traditional discovery/development processes to accommodate early human studies as part of the drug candidate selection processes.

Professor Colin Garner, Xceleron's CEO commented, "This collaborative Agreement is the result of Servier and Xceleron working together for a number of years to use the AMS technology to accelerate drug development."

"It shows the far-sightedness of Servier in introducing novel enabling technologies to change their paradigm of drug development". 

Dr Bernard Marchand, Servier's Director of Biopharmacy commented, "we are delighted to be working with Xceleron who have pioneered the human Phase 0 microdose approach."

"Our positive experience as one of the supporters of the CREAM trial has enabled us to see the potential utility of AMS in improving our drug selection procedures".

Advertisement